Watermark
  Back to Search Results

BGB-283/PD-0325901-AU-001

Completed

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-283/PD-0325901-AU-001

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT03905148

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

No Study Documents

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

No Study Documents